The mineralocorticoid receptor antagonist did not reduce primary outcomes in the CLEAR SYNERGY trial, but there was a suggestion that it did prevent new or worsening heart failure.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback